Compare Ferrari NV (RACE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Repligen Corporation Common Stock — how do they compare? Ferrari NV trades at $391.46 (market cap $68.43B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Ferrari NV is far larger — about 6.1× Repligen Corporation Common Stock's market cap, and Ferrari NV pays a 1.09% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Repligen Corporation Common Stock for 0 Days on average.
| RACE | RGEN | |
|---|---|---|
Market Cap | $68.43B | $11.31B |
Volume | 343,086 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $194.57 |
52-Week Low | $314.63 | $102.87 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $70.30B | $11.20B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $391.60, up 0.61% with strong fundamentals including 22.25% net margins and consistent earnings beats. The stock shows bearish technical signals despite positive analyst sentiment with a $462.75 consensus target. Recent news highlights institutional buying and a €250 million share buyback program, while financials reveal robust revenue growth from $5.1B in 2022 to $7.15B in 2025.
Outlook remains positive given Ferrari's premium brand positioning and earnings momentum, though valuation multiples appear stretched with a P/E of 37.4. Key risks include economic sensitivity to luxury demand and execution of electric vehicle initiatives. The 18% upside to analyst targets suggests potential reward, but investors should weigh high valuations against growth sustainability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
